Status:
COMPLETED
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Lead Sponsor:
Cumberland Pharmaceuticals
Conditions:
Bacterial Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Eligibility Criteria
Inclusion
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.
Exclusion
- Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
771 Patients enrolled
Trial Details
Trial ID
NCT00124020
Start Date
January 1 2005
End Date
May 1 2007
Last Update
January 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center, Infectious Disease Unit
Tel Litwinsky, Israel, 52621